Simian virus-40 as a gene therapy vector

Maria Vera Ugalde, Puri Fortes

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Simian virus-40 (SV40), an icosahedral papovavirus, has recently been modified to serve as a gene delivery vector. Recombinant SV40 vectors (rSV40) are good candidates for gene transfer, as they display some unique features: SV40 is a well-known virus, nonreplicative vectors are easy-to-make, and can be produced in titers of 1012 IU/ml. They also efficiently transduce both resting and dividing cells, deliver persistent transgene expression to a wide range of cell types, and are nonimmunogenic. Present disadvantages of rSV40 vectors for gene therapy are a small cloning capacity and the possible risks related to random integration of the viral genome into the host genome. Considerable efforts have been devoted to modifing this virus and setting up protocols for viral production. Preliminary therapeutic results obtained both in tissue culture cells and in animal models for heritable and acquired diseases indicate that rSV40 vectors are promising gene transfer vehicles. This article reviews the work performed with SV40 viruses as recombinant vectors for gene transfer. A summary of the structure, genomic organization, and life cycle of wild-type SV40 viruses is presented. Furthermore, the strategies utilized for the development, production, and titering of rSV40 vectors are discussed. Last, the therapeutic applications developed to date are highlighted.

Original languageEnglish (US)
Pages (from-to)271-282
Number of pages12
JournalDNA and Cell Biology
Volume23
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Simian virus 40
Genetic Therapy
Viruses
Genes
Viral Genome
Life Cycle Stages
Transgenes
Organism Cloning
Animal Models
Cell Culture Techniques
Genome
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

Simian virus-40 as a gene therapy vector. / Vera Ugalde, Maria; Fortes, Puri.

In: DNA and Cell Biology, Vol. 23, No. 5, 05.2004, p. 271-282.

Research output: Contribution to journalReview article

Vera Ugalde, M & Fortes, P 2004, 'Simian virus-40 as a gene therapy vector', DNA and Cell Biology, vol. 23, no. 5, pp. 271-282. https://doi.org/10.1089/104454904323090903
Vera Ugalde, Maria ; Fortes, Puri. / Simian virus-40 as a gene therapy vector. In: DNA and Cell Biology. 2004 ; Vol. 23, No. 5. pp. 271-282.
@article{ecf0af322a614486a8ff4c7aedcb7a8c,
title = "Simian virus-40 as a gene therapy vector",
abstract = "Simian virus-40 (SV40), an icosahedral papovavirus, has recently been modified to serve as a gene delivery vector. Recombinant SV40 vectors (rSV40) are good candidates for gene transfer, as they display some unique features: SV40 is a well-known virus, nonreplicative vectors are easy-to-make, and can be produced in titers of 1012 IU/ml. They also efficiently transduce both resting and dividing cells, deliver persistent transgene expression to a wide range of cell types, and are nonimmunogenic. Present disadvantages of rSV40 vectors for gene therapy are a small cloning capacity and the possible risks related to random integration of the viral genome into the host genome. Considerable efforts have been devoted to modifing this virus and setting up protocols for viral production. Preliminary therapeutic results obtained both in tissue culture cells and in animal models for heritable and acquired diseases indicate that rSV40 vectors are promising gene transfer vehicles. This article reviews the work performed with SV40 viruses as recombinant vectors for gene transfer. A summary of the structure, genomic organization, and life cycle of wild-type SV40 viruses is presented. Furthermore, the strategies utilized for the development, production, and titering of rSV40 vectors are discussed. Last, the therapeutic applications developed to date are highlighted.",
author = "{Vera Ugalde}, Maria and Puri Fortes",
year = "2004",
month = "5",
doi = "10.1089/104454904323090903",
language = "English (US)",
volume = "23",
pages = "271--282",
journal = "DNA and Cell Biology",
issn = "1044-5498",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Simian virus-40 as a gene therapy vector

AU - Vera Ugalde, Maria

AU - Fortes, Puri

PY - 2004/5

Y1 - 2004/5

N2 - Simian virus-40 (SV40), an icosahedral papovavirus, has recently been modified to serve as a gene delivery vector. Recombinant SV40 vectors (rSV40) are good candidates for gene transfer, as they display some unique features: SV40 is a well-known virus, nonreplicative vectors are easy-to-make, and can be produced in titers of 1012 IU/ml. They also efficiently transduce both resting and dividing cells, deliver persistent transgene expression to a wide range of cell types, and are nonimmunogenic. Present disadvantages of rSV40 vectors for gene therapy are a small cloning capacity and the possible risks related to random integration of the viral genome into the host genome. Considerable efforts have been devoted to modifing this virus and setting up protocols for viral production. Preliminary therapeutic results obtained both in tissue culture cells and in animal models for heritable and acquired diseases indicate that rSV40 vectors are promising gene transfer vehicles. This article reviews the work performed with SV40 viruses as recombinant vectors for gene transfer. A summary of the structure, genomic organization, and life cycle of wild-type SV40 viruses is presented. Furthermore, the strategies utilized for the development, production, and titering of rSV40 vectors are discussed. Last, the therapeutic applications developed to date are highlighted.

AB - Simian virus-40 (SV40), an icosahedral papovavirus, has recently been modified to serve as a gene delivery vector. Recombinant SV40 vectors (rSV40) are good candidates for gene transfer, as they display some unique features: SV40 is a well-known virus, nonreplicative vectors are easy-to-make, and can be produced in titers of 1012 IU/ml. They also efficiently transduce both resting and dividing cells, deliver persistent transgene expression to a wide range of cell types, and are nonimmunogenic. Present disadvantages of rSV40 vectors for gene therapy are a small cloning capacity and the possible risks related to random integration of the viral genome into the host genome. Considerable efforts have been devoted to modifing this virus and setting up protocols for viral production. Preliminary therapeutic results obtained both in tissue culture cells and in animal models for heritable and acquired diseases indicate that rSV40 vectors are promising gene transfer vehicles. This article reviews the work performed with SV40 viruses as recombinant vectors for gene transfer. A summary of the structure, genomic organization, and life cycle of wild-type SV40 viruses is presented. Furthermore, the strategies utilized for the development, production, and titering of rSV40 vectors are discussed. Last, the therapeutic applications developed to date are highlighted.

UR - http://www.scopus.com/inward/record.url?scp=2542554962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542554962&partnerID=8YFLogxK

U2 - 10.1089/104454904323090903

DO - 10.1089/104454904323090903

M3 - Review article

C2 - 15169607

AN - SCOPUS:2542554962

VL - 23

SP - 271

EP - 282

JO - DNA and Cell Biology

JF - DNA and Cell Biology

SN - 1044-5498

IS - 5

ER -